Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium III

2389 - Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study


30 Sep 2019


Presidential Symposium III


Tumour Site

Oesophageal Cancer


Byoung Chul Cho


Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394


B.C. Cho1, K. Kato2, M. Takahashi3, M. Okada4, C. Lin5, K. Chin6, S. Kadowaki7, M. Ahn8, Y. Hamamoto9, Y. Doki10, C. Yen11, Y. Kubota12, S. Kim13, C. Hsu14, E. Holtved15, I. Xynos16, M. Kodani17, Y. Kitagawa18

Author affiliations

  • 1 Medical Oncology Dept, Yonsei University, 03722 - Seoul/KR
  • 2 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo/JP
  • 3 Clinical Oncology, Institute of Developpment, Aging Cancer, Tohoku University, 980-8575 - Sendai/JP
  • 4 Surgical Oncology, Hiroshima University, 734-8551 - Hiroshima/JP
  • 5 Hematology And Oncology, China Medical University Hospital And School Of Pharmacy, China Medical University Hospital, Taichung City/TW
  • 6 Medical Oncology Dept, Cancer Institute Hospital, Tokoyo/JP
  • 7 Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 8 Hematology-oncology, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 9 Keio Cancer Center, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 10 Gastroenterological Surgery, Osaka University Hospital, Osaka/JP
  • 11 Medical Oncology Dept, Taipei Veterans General Hospital, 11217 - Taipei City/TW
  • 12 Medical Oncology, Showa University Hospital, Tokyo/JP
  • 13 Medical Oncology Dept, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 14 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei City/TW
  • 15 Clinical Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 16 Global Clinical Research, BMS, 08648 - Princeton/US
  • 17 Department Of Oncology, ONO Pharmaceutical Co. Ltd.-Tokyo Office, 101-0041 - Tokyo/JP
  • 18 Surgical Oncology, Keio University School of Medicine, 160-8582 - Tokyo/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2389


Chemotherapy (CT) for advanced ESCC offers poor long-term survival. We report the final analysis from the phase III ATTRACTION-3 study of the programmed death (PD)-1 inhibitor nivolumab (NIVO) versus CT in patients (pts) with unresectable advanced or recurrent ESCC refractory or intolerant to 1 prior fluoropyrimidine/platinum-based CT.


Pts were enrolled regardless of PD-ligand 1 (PD-L1) expression and randomized 1:1 to either NIVO (240 mg Q2W) or investigator’s choice of paclitaxel or docetaxel. Primary endpoint was overall survival (OS).


419 pts were randomized (NIVO = 210, CT = 209). At a minimum follow-up of 17.6 months (mo; time from randomization of the last pt to data cutoff), NIVO showed a statistically significant improvement in OS vs CT (HR for death 0.77 [95% CI, 0.62–0.96; P = 0.02]; median OS, 10.9 vs 8.4 mo; Table). The proportion of pts alive at 18 mo was numerically larger with NIVO vs CT (31% vs 21%; Table). HRs for the risk of death favored NIVO over CT across tumor PD-L1 expression levels (PD-L1 ≥1%, HR 0.69 [95% CI, 0.51 to 0.94]; PD-L1 <1%, HR 0.84 [95% CI, 0.62 to 1.14]). The Table shows objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS). Fewer treatment-related adverse events (TRAEs) were reported with NIVO (any grade, 66%; grade 3–4, 18%) vs CT (any grade, 95%; grade 3–4, 63%; Table). NIVO showed a statistically significant overall improvement in quality of life vs CT through on-treatment week 42 in both the EQ-5D visual analog scale (least square [LS] mean, 6.9; 95% CI, 3.0–10.9; P < 0.001) and EQ-5D utility index (LS mean, 0.076; 95% CI, 0.011–0.142; P = 0.023).Table:


Efficacy (all randomized pts)NIVO N = 210CT N = 209
Median OS, mo (95% CI)10.9 (9.2–13.3)8.4 (7.2–9.9)
HR (95% CI; P-value)0.77 (0.62–0.96; P = 0.02)
12-mo rate, % (95% CI)47 (40–54)34 (28–41)
18-mo rate, % (95% CI)31 (24–37)21 (15–27)
ORR, n (%)a33 (19)34 (22)
95% CI14–2615–29
Median DOR,b mo (95% CI)6.9 (5.4–11.1)3.9 (2.8–4.2)
Median PFS, mo (95% CI)1.7 (1.5–2.7)3.4 (3.0–4.2)
HR (95% CI)1.08 (0.87–1.34)
6-mo rate, % (95% CI)24 (19–30)17 (12–23)
12-mo rate, % (95% CI)12 (8–17)7 (4–12)
Safety (all treated pts)N = 209N = 208
Pts with TRAEs, n (%)137 (66)198 (95)
Grade 3–4 TRAEs, n (%)38 (18)131 (63)
Pts with serious TRAEs, n (%)33c (16)47 (23)
Pts with TRAEs leading to discontinuation, n (%)18 (9)19 (9)

Assessed in randomized pts who had target lesion measurements at baseline: NIVO, N = 171; CT, N = 158.


Time from date of first response to date of first documented tumor progression or death.


One grade 4 serious TRAE was not reported before the database lock and is not captured here.


NIVO demonstrated superior OS and a favorable safety profile vs CT in pts with previously treated advanced ESCC, with survival benefit observed regardless of tumor PD-L1 expression. NIVO may represent a new standard second-line treatment option for pts with advanced ESCC.

Clinical trial identification


Editorial acknowledgement

Professional medical writing assistance and editorial assistance were provided by Jennifer Granit, PhD, and Christine Craig of Parexel, funded by Bristol-Myers Squibb.

Legal entity responsible for the study

Ono Pharmaceutical Co, Bristol-Myers Squibb.


Ono Pharmaceutical Co, Bristol-Myers Squibb.


B.C. Cho: Research grant / Funding (self): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD ; Licensing / Royalties: Champions Oncology; Shareholder / Stockholder / Stock options: TheraCanVac Inc; Honoraria (self): Novatis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Advisory / Consultancy: Novatis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takega, MSD; Speaker Bureau / Expert testimony: Novartis. K. Kato: Advisory / Consultancy: Ono Pharmaceutical, BeiGene, MSD, Oncolys BioPharma; Research grant / Funding (institution): Ono Pharmaceutical, Shionogi, MSD, Beigene. M. Takahashi: Research grant / Funding (self): Ono Pharmaceutical; Speaker Bureau / Expert testimony: Ono Pharmaceutical, Brystol-Myers Squibb, Daichi-Sankyo. M. Okada: Speaker Bureau / Expert testimony: Tahio Pharmaceutical, Johnson & Johnson, Coviden, Lilly, Chugai Pharma; Research grant / Funding (institution): Taiho Pharmaceutical, Nippon Kayaku, Chugai Pharma, Coviden, Johnson & Johnson, Daiichi Sanko, Yakult Honsha, Lilly Japan, Nihon Medi-Physics, Pfizer, Mochida Pharmaceuticals Co. Ltd, Shionogi. S. Kadowaki: Research grant / Funding (institution): Ono Pharmaceutical, Lilly Japan, Taiho Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb. Y. Doki: Speaker Bureau / Expert testimony: Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Daiichi Sankyo, Yakult Honsha, Takeda Pharmaceutical, Kaken Pharmaceutical, Abbott Japan; Research grant / Funding (self): Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Eli Lilly, MSD, Daiichi Sankyo, Yakult Honsha, Takeda Pharmaceutical, Kaken Pharmaceutical, Abbott Japan, Eisai, Shionogi . C. Yen: Honoraria (self): Lilly, Merck Sharp & Dohme, Amgen, Eisai; Advisory / Consultancy: Lilly, Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Lilly, Ono Pharmaceutical, Eisai, Effective Pharmaceuticals. S. Kim: Research grant / Funding (institution): Novartis, Genzyme, Dongkook Pharma. C. Hsu: Advisory / Consultancy: Ono Pharmaceutical, Lilly, MSD, Novartis; Honoraria (self): Bristol-Myers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme; Research grant / Funding (institution): Ono Pharmaceutical, AstraZeneca, MSD, Genentech. I. Xynos: Shareholder / Stockholder / Stock options: Bristol-Myers Squibb. M. Kodani: Shareholder / Stockholder / Stock options: Ono Pharmaceutical Co. Ltd. Y. Kitagawa: Honoraria (self): Ethicon, Olympus, Ono Pharmaceutical, Tahi Pharmaceutical, Chugai Pharma, Nippon Kayaku, Asahi Kasei; Research grant / Funding (institution): Astellas, Otsuka, Kaken Pharmaceutical, Kyowa Hakko Kirin, Kowa, CSL Behring, Shionogi, Saiichi Sankyo, Taiho Pharmaceutical, Takeda, Chugai Pharma, Tsumura & Co., Teijin Pharma, Medtronic, Boehringer Ingelheim, Merck Serono, Novartis, Ajinomoto, Asahi Ka. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.